UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 16, 2004
La Jolla Pharmaceutical Company
| Delaware | 0-24274 | 33-0361285 | ||
|
|
||||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6455 Nancy Ridge Drive, San Diego, California | 92121 | |||
|
|
||||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
N/A
| Item 5. Other Events and Required FD Disclosure | ||||||||
| Item 7. Financial Statements, Pro Forma Financial Information and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events and Required FD Disclosure.
On February 16, 2004, La Jolla Pharmaceutical Company issued a press release announcing that its New Drug Application for Riquent® had been accepted for review by the United States Food and Drug Administration. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following exhibits are filed with this report on Form 8-K:
| Exhibit Number |
Description of Exhibit | |
|
|
||
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LA JOLLA PHARMACEUTICAL COMPANY | ||||
| Date: February 17, 2004 | By: | /s/ Steven B. Engle | ||
| Steven B. Engle | ||||
| Chairman and Chief Executive Officer | ||||
EXHIBIT INDEX
| Exhibit Number |
Description of Exhibit | |
|
|
||
| 99.1 | Press Release |